Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia - PubMed (original) (raw)

Comparative Study

Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia

Felicia B Axelrod et al. Pediatr Res. 2011 Nov.

Abstract

Familial dysautonomia (FD) is caused by an intronic splice mutation in the IKBKAP gene that leads to partial skipping of exon 20 and tissue-specific reduction in I-κ-B kinase complex-associated protein/elongation protein 1 (IKAP/ELP-1) expression. Kinetin (6-furfurylaminopurine) has been shown to improve splicing and increase WT IKBKAP mRNA and IKAP protein expression in FD cell lines and carriers. To determine whether oral kinetin treatment could alter mRNA splicing in FD subjects and was tolerable, we administered kinetin to eight FD individuals homozygous for the splice mutation. Subjects received 23.5 mg/Kg/d for 28 d. An increase in WT IKBKAP mRNA expression in leukocytes was noted after 8 d in six of eight individuals; after 28 d, the mean increase compared with baseline was significant (p = 0.002). We have demonstrated that kinetin is tolerable in this medically fragile population. Not only did kinetin produce the desired effect on splicing in FD patients but also that effect seems to improve with time despite lack of dose change. This is the first report of a drug that produces in vivo mRNA splicing changes in individuals with FD and supports future long-term trials to determine whether kinetin will prove therapeutic in FD patients.

PubMed Disclaimer

Figures

Figure 1

Venous plasma levels of kinetin after administration (n = 8, data are mean±SEM). Time zero represents the time of drug administration.

Figure 2

The percent of IKBKAP transcript produced that include exon 20 at baseline, after 8 days of receiving kinetin and after 28 days of receiving kinetin. Open squares show individual data. Subject number is to the left of the baseline values. Bar charts show mean±SEM; p =0.002.

References

1. Axelrod FB. Familial dysautonomia. Muscle Nerve. 2004;29:352–363. - PubMed
1. Axelrod FB, Gold-von Simson G. Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet J Rare Dis. 2007;2:39. - PMC - PubMed
1. Norcliffe-Kaufmann L, Axelrod F, Kaufmann H. Afferent baroreflex failure in familial dysautonomia. Neurology. 2010;75:1904–1911. - PMC - PubMed
1. Axelrod FB, Goldberg JD, Ye XY, Maayan C. Survival in familial dysautonomia: impact of early intervention. J Pediatr. 2002;141:518–523. - PubMed
1. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF. Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet. 2001;68:598–605. - PMC - PubMed

Kinetin improves IKBKAP mRNA splicing in patients with familial dysautonomia - PubMed (original) (raw)